Open Access Repository

Identifying genetic biomarkers predicting response to anti-vascular endothelial growth factor injections in diabetic macular edema

Gurung, RL, Fitzgerald, LM ORCID: 0000-0002-6882-2698, Liu, E, McComish, BJ ORCID: 0000-0003-1940-0007, Kaidonis, G, Ridge, B, Hewitt, AW ORCID: 0000-0002-5123-5999, Vote, BJ, Verma, N, Craig, JE and Burdon, KP ORCID: 0000-0001-8217-1249 2022 , 'Identifying genetic biomarkers predicting response to anti-vascular endothelial growth factor injections in diabetic macular edema' , International Journal of Molecular Sciences, vol. 23, no. 7 , doi:

PDF (Published version)
150209 - Identi...pdf | Download (652kB)

| Preview


Intraocular anti-vascular endothelial growth factor (VEGF) therapies are the front-line treatment for diabetic macular edema (DME); however, treatment response varies widely. This study aimed to identify genetic determinants associated with anti-VEGF treatment response in DME. We performed a genome-wide association study on 220 Australian patients with DME treated with anti-VEGF therapy, genotyped on the Illumina Global Screening Array, and imputed to the Haplotype Reference Consortium panel. The primary outcome measures were changes in central macular thickness (CMT in microns) and best-corrected visual acuity (BCVA in ETDRS letters) after 12 months. Association between single nucleotide polymorphism (SNP) genotypes and DME outcomes were evaluated by linear regression, adjusting for the first three principal components, age, baseline CMT/BCVA, duration of diabetic retinopathy, and HbA1c. Two loci reached genome-wide significance (p −8) for association with increased CMT: a single SNP on chromosome 6 near CASC15 (rs78466540, p = 1.16 × 10−9) and a locus on chromosome 12 near RP11-116D17.1 (top SNP rs11614480, p = 2.69 × 10−8). Four loci were significantly associated with reduction in BCVA: two loci on chromosome 11, downstream of NTM (top SNP rs148980760, p = 5.30 × 10−9) and intronic in RP11-744N12.3 (top SNP rs57801753, p = 1.71 × 10−8); one near PGAM1P1 on chromosome 5 (rs187876551, p = 1.52 × 10−8); and one near TBC1D32 on chromosome 6 (rs118074968, p = 4.94 × 10−8). In silico investigations of each locus identified multiple expression quantitative trait loci and potentially relevant candidate genes warranting further analysis. Thus, we identified multiple genetic loci predicting treatment outcomes for anti-VEGF therapies in DME. This work may potentially lead to managing DME using personalized treatment approaches.

Item Type: Article
Authors/Creators:Gurung, RL and Fitzgerald, LM and Liu, E and McComish, BJ and Kaidonis, G and Ridge, B and Hewitt, AW and Vote, BJ and Verma, N and Craig, JE and Burdon, KP
Keywords: anti-vascular endothelial growth factor, diabetic macular edema, genome-wide association, diabetic retinopathy, treatment response, genetics, pharmacogenetics
Journal or Publication Title: International Journal of Molecular Sciences
Publisher: MDPI AG
ISSN: 1422-0067
DOI / ID Number:
Copyright Information:

Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons 4.0 International (CC BY 4.0) license (

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page